Obtaining optimum corneal tissue for transplant

Article

A team in the Philippines has defined criteria that need to be met in order to obtain an optimum tissue quality for corneal grafts.

A team in the Philippines has defined criteria that need to be met in order to obtain an optimum tissue quality for corneal grafts. The quality of corneal grafts can be affected by factors including the time and season of the post-mortem graft harvest, according to the study.

Dr Charish F. Daffon and colleagues conducted a retrospective review of corneal donor records (n=1955) from 2000–2005 and tabulated donor data to establish criteria for harvesting optimal corneal buttons for tissue eye banking. Data on 2797 corneal buttons were analysed.

The team found that factors influencing endothelial corneal rating and overall button quality were age of donor (≤32 years for optimum quality), duration of time between death and preservation (≤7.1 hours for optimum tissue quality - note that this is significantly shorter than the internationally recognised 12-hour standard), technician extracting the tissue and month of harvest (December–February).

The researchers concluded that there are several factors governing the quality of corneal tissue extracted post-mortem for transplantation.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.